Immunic to Join Evercore ISI Healthcare Conference in December

Immunic, Inc., a biotechnology company focusing on neurologic and gastrointestinal diseases, is set to participate in the 8th Annual Evercore ISI Healthcare Conference. Scheduled for December 2-4, 2025, in Coral Gables, FL, the conference will feature a fireside chat with Immunic's CEO, Dr. Daniel Vitt, on December 4 at 9:35 am ET.

Moreover, the company will hold one-on-one investor meetings led by Dr. Vitt and Jason Tardio, the President and COO. Interested parties can arrange meetings through Evercore ISI or contact Jessica Breu at Immunic.

With its lead program, vidofludimus calcium, in phase 3 trials for multiple sclerosis, Immunic remains committed to developing novel therapies. Details and the webcast of the conference will be available on Immunic’s website.